



07-11-05

IFW

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Chandrakumar et al.  
Serial No: 10/718,328  
Filed: November 20, 2003  
For: Heterocyclic Glycyl  $\beta$ -Alanine Derivatives  
Art Unit: 1653  
Confirmation No.: 1053  
Examiner: David Lukton  
Attorney Docket No.: 3077/0A/US  
Pfizer Ref: 31103A/USA  
HDP Ref: 6794-000092/US/DVA

July 8, 2005

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Madam/Sir:

To comply with 37 C.F.R. §1.97 and §1.98, Applicants have enclosed a Form 1449 and copies of documents cited on that form. In accordance with MPEP §609 and §707.05(b), Applicants respectfully request that each document listed be given thorough consideration, and that the Examiner cite each document of record in the prosecution history of the present application by initialing the Form 1449 next to each document. Applicants request such initialing even if the Examiner does not consider: (1) a document to be sufficiently pertinent to use in a rejection; (2) a document to be prior art for any reason; or (3) that the guidelines for citation have been fully complied with respecting a particular document. Applicants make this request so that each document becomes cited on the face of a patent issuing on the present application.

Applicants submit this information disclosure statement in compliance with the duty to disclose information material to patentability under 37 CFR §1.56, but by listing such documents are not admitting that such documents are necessarily relevant or prior art. Applicants intend no

EV 726254236 US

representation that the listed documents represent the results of a complete search. Applicants anticipate that the Examiner, in the normal course of examination, will make an independent search consistent with 37 CFR §1.104, and, in the course of such search, will review for relevance every document listed on the attached form even if not initialed.

This application is a divisional of U.S. Application Serial No. 09/289,140 (filed April 8, 1999, issued as U.S. Patent No. 6,689,754). Applicants presume that the Examiner has access to the file history of the above-referenced application. Applicants further presume that the Examiner is aware of the issues raised and the scope of claims in that case, and will take them into account when examining this patent application. Upon request from the Examiner, Applicants can provide copies of the substantive Office actions or any other information relating to that case, to the extent Applicants have such information in their possession.

Applicants request early and favorable consideration of this application.

\* \* \* \* \*

Applicants believe that the cited references were enclosed with the Information Disclosure Statement filed on July 8, 2004. Applicants have enclosed the post card indicating this. Applicants, however, are resubmitting the references in response to the June 10, 2005 Office action, which indicates that the Patent Office does not have the copies. Applicants do not believe that they owe a fee for this submission. If, however, Applicants do owe any such fee(s), the Commissioner is hereby authorized to charge such fee(s) to Deposit Account No. **08-0750**. In addition, if there is ever any other fee deficiency or overpayment under 37 C.F.R. §1.16 or §1.17 in connection with this patent application, the Commissioner is hereby authorized to charge such deficiency or overpayment to Deposit Account No. **08-0750**.

The Examiner is requested to call the undersigned if any questions arise that can be addressed over the phone to expedite examination of this application.

Application No. 10/718,328  
Information Disclosure Statement  
July 8, 2005



Respectfully submitted,

A handwritten signature in black ink, appearing to be "D. M. Gryte", written over a horizontal line.

David M. Gryte, PTO Reg. No. 41,809  
Harness, Dickey & Pierce  
7700 Bonhomme, Suite 400  
St. Louis, Missouri 63105  
(314) 726-7500 (tel)  
(314) 726-7501 (fax)

**CERTIFICATE OF MAILING UNDER 37 CFR § 1.8**


I certify that this correspondence is being deposited with the U.S. Postal Service on **July 8, 2005** with sufficient postage as first class mail (including Express Mail per MPEP § 512), and addressed to **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450**.

A handwritten signature in black ink, appearing to be "D. M. Gryte", written over a horizontal line.

David M. Gryte

DMG/JPG/cml  
Enclosures

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET No.	SERIAL No.
<b>PATENT AND TRADEMARK OFFICE</b> <b>INFORMATION DISCLOSURE CITATION</b> (Use several sheets if necessary)		3077/0A/US 31103A/USA (6794-000092/DVA)	10/718,328
		APPLICANT	
		Chandrakumar et al	
Sheet 1 of 2		FILING DATE	GROUP
		November 20, 2003	1653



U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date

FOREIGN PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
1.		Adamis et al., Increased Vascular Endothelial Growth Factor Levels in the Vitreous of Eyes with Proliferative Diabetic Retinopathy, <i>American Journal of Ophthalmology</i> , Vol. 118, pp. 445-450, October 1994
2.		Brooks et al., Integrin $\alpha_v\beta_3$ Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels, <i>Cell</i> , Vol. 79, pp. 1157-1164, December 1994
3.		Brooks et al., Requirement of Vascular Integrin $\alpha_v\beta_3$ for Angiogenesis, <i>Science</i> , Vol. 264, pp. 569-571, April 1994
4.		Choi et al., Inhibition of neointimal hyperplasia by blocking $\alpha_v\beta_3$ integrin with a small peptide antagonist <i>Gpen</i> GRGDSPCA, <i>J. Vasc. Surg.</i> , Vol. 19(1), pp. 125-134, 1994
5.		Fisher et al., Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein, <i>Endocrinology</i> , Vol. 132, No. 3, pp. 1411-1413, 1993
6.		Montgomery et al., Integrin $\alpha_v\beta_3$ rescues melanoma cells from apoptosis in three-dimensional dermal collagen, <i>Proc. Natl Acad. Sci. USA</i> , Vol. 91, pp. 8856-8860, September 1994
7.		Peacock et al., Angiogenesis Inhibition Suppresses Collagen Arthritis, <i>J. Exp. Med.</i> , Vol. 175, pp. 1135-1138, April 1992

Examiner: David Lukton	Date Considered:
------------------------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


**EV 726254236 US**

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p><b>PATENT AND TRADEMARK OFFICE</b></p> <p><b>INFORMATION DISCLOSURE CITATION</b></p> <p>(Use several sheets if necessary)</p> <p>Sheet 2 of 2</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	3077/0A/US 31103A/USA (6794-000092/DVA)	10/718,328
	APPLICANT	
	Chandrakumar et. al	
	FILING DATE	GROUP
	November 20, 2003	Unknown

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
8.		Sato et al., Echistatin Is a Potent Inhibitor of Bone Resorption in Culture, <i>J. Cell Biology</i> , Vol. 111, pp. 1713-1723, October 1990
9.		Seftor et al., Role of the $\alpha_v\beta_3$ integrin in human melanoma cell invasion, <i>Proc. Natl. Acad. Sci. USA</i> , Vol. 89, pp. 1557-1561, March 1992
10		White, J.M., Integrins as virus receptors, <i>Current Biology</i> , Vol. 3(9), pp. 596-599, 1993

Examiner: David Lukton	Date Considered:
------------------------	------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant:	Chandrakumar et al.	Client Matter #	3077/0A (6794-92/US/DVA)
Serial/Patent #	10/718,328	Filing/Issue Date:	November 20, 2003
Title:	Heterocyclic Glycyl $\beta$ -Alanine Derivatives		
Please acknowledge receipt of: Transmittal (1 page) Information Disclosure Statement (2 pages) HDP Form-1449 (2 pages) References (11)		<div style="text-align: center;"> <b>DOCKETED</b>  <b>JUL 19 2004</b> </div> <div style="text-align: center;">  </div>	
By stamping and returning to Harness, Dickey & Pierce, P.L.C.		<div style="text-align: center;"> <b>EV 298497168 US</b>          Via Express Mail Label No. EV 298497168 US       </div>	
		<div style="text-align: center;"> <b>RECEIVED</b>  <b>JUL 16 2004</b>          USPTO Date Stamp          HARNESS, DICKEY &amp; PIERCE          ST. LOUIS, MISSOURI       </div>	
Mailed:	July 8, 2004	Attorney:	James E. Davis

**EV 726254236 US**